President-elect Donald Trump threatened Tuesday to place new tariffs on imports from Denmark unless the country gives up control of Greenland, news that dented the stocks of some of Denmark's most ...

FOIA requests to the federal government often are signals. They can be an important early warning of bad publicity, litigation to come, or uncertainties to be hedged and gamed out. When the flow of ...

BBI Solutions Limited ("BBI"), global leader in the development and manufacture of IVD reagents, announces a CEO succession. After ...

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the "Company”) announced today that its SomaScan™ Platform played a pivotal role in a study ...

European markets are expected to open broadly lower Wednesday. The U.K.'s FTSE 100 index is expected to open 4 points lower ...

Can this diabetes-control breakthrough also become the answer to obesity? From Hollywood’s red carpets to affluent Indians, ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

Loomis Sayles, an investment management company, released its “International Growth Fund” third quarter 2024 investor letter.

Both Eli Lilly and Novo Nordisk have invested in GLP-1 injectables manufacturing sites, with more capacity on the way. With a ribbon-cutting ceremony and tour on June 14, 2024, Lilly showed off its ...